Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

An inhibitory effect of tumor necrosis factor-alpha antagonist to gene expression in monocrotaline-induced pulmonary hypertensive rats model.

Kwon JH, Kim KC, Cho MS, Kim HS, Sohn S, Hong YM.

Korean J Pediatr. 2013 Mar;56(3):116-24. doi: 10.3345/kjp.2013.56.3.116.

2.

Changes of gene expression after bone marrow cell transfusion in rats with monocrotaline-induced pulmonary hypertension.

Kim KC, Lee HR, Kim SJ, Cho MS, Hong YM.

J Korean Med Sci. 2012 Jun;27(6):605-13. doi: 10.3346/jkms.2012.27.6.605.

3.

Changes of pulmonary pathology and gene expressions after simvastatin treatment in the monocrotaline-induced pulmonary hypertension rat model.

Lee YH, Kim KC, Cho MS, Hong YM.

Korean Circ J. 2011 Sep;41(9):518-27. doi: 10.4070/kcj.2011.41.9.518.

4.

Gene expression of endothelin-1 and endothelin receptor a on monocrotaline-induced pulmonary hypertension in rats after bosentan treatment.

Lim KA, Kim KC, Cho MS, Lee BE, Kim HS, Hong YM.

Korean Circ J. 2010 Sep;40(9):459-64. doi: 10.4070/kcj.2010.40.9.459.

5.
6.

Effect of small hairpin RNA targeting endothelin-converting enzyme-1 in monocrotaline-induced pulmonary hypertensive rats.

Son JS, Kim KC, Kim BK, Cho MS, Hong YM.

J Korean Med Sci. 2012 Dec;27(12):1507-16. doi: 10.3346/jkms.2012.27.12.1507.

7.

[Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats].

Li XL, Guan RJ, Xu QH, Wu ZY.

Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Mar;39(3):247-53. Chinese.

PMID:
21609531
8.

The effect of sildenafil on right ventricular remodeling in a rat model of monocrotaline-induced right ventricular failure.

Bae HK, Lee H, Kim KC, Hong YM.

Korean J Pediatr. 2016 Jun;59(6):262-70. doi: 10.3345/kjp.2016.59.6.262.

9.

The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.

Guerard P, Rakotoniaina Z, Goirand F, Rochette L, Dumas M, Lirussi F, Bardou M.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Sep;373(6):401-14.

PMID:
16896805
10.
11.

Sildenafil limits monocrotaline-induced pulmonary hypertension in rats through suppression of pulmonary vascular remodeling.

Yen CH, Leu S, Lin YC, Kao YH, Chang LT, Chua S, Fu M, Wu CJ, Sun CK, Yip HK.

J Cardiovasc Pharmacol. 2010 Jun;55(6):574-84. doi: 10.1097/FJC.0b013e3181d9f5f4.

PMID:
20224427
12.
13.

Role of nitric oxide and endothelin-1 in monocrotaline-induced pulmonary hypertension in rats.

Mathew R, Zeballos GA, Tun H, Gewitz MH.

Cardiovasc Res. 1995 Nov;30(5):739-46.

PMID:
8595621
14.

All-trans retinoic acid in pulmonary vascular structural remodeling in rats with pulmonary hypertension induced by monocrotaline.

Qin Y, Zhou A, Ben X, Shen J, Liang Y, Li F.

Chin Med J (Engl). 2001 May;114(5):462-5.

PMID:
11780404
15.
16.

Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension.

Homma N, Morio Y, Takahashi H, Yamamoto A, Suzuki T, Sato K, Muramatsu M, Fukuchi Y.

Respiration. 2006;73(1):105-12.

PMID:
16432296
17.

Effect of thrombomodulin on the development of monocrotaline-induced pulmonary hypertension.

Yamada Y, Maruyama J, Zhang E, Okada A, Yokochi A, Sawada H, Mitani Y, Hayashi T, Suzuki K, Maruyama K.

J Anesth. 2014 Feb;28(1):26-33. doi: 10.1007/s00540-013-1663-z.

PMID:
23817901
18.

Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension.

Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, Yano M, Yamaguchi I, Sugishita Y, Goto K.

Circ Res. 1993 Nov;73(5):887-97.

19.

Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats.

Lu J, Shimpo H, Shimamoto A, Chong AJ, Hampton CR, Spring DJ, Yada M, Takao M, Onoda K, Yada I, Pohlman TH, Verrier ED.

J Thorac Cardiovasc Surg. 2004 Dec;128(6):850-9.

20.

The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.

Rakotoniaina Z, Guerard P, Lirussi F, Goirand F, Rochette L, Dumas M, Bardou M.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Dec;374(3):195-206.

PMID:
17102939

Supplemental Content

Support Center